Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of [14C]-NV-5138 in Healthy Male Subjects
NCT05152680Phase 1Completed
- Sponsor
- Navitor Pharmaceuticals
- Start
- Nov 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mefluleucine in major depressive disorder (MDD), sponsored by Navitor Pharmaceuticals. Primary endpoint: Cumulative total radioactivity in urine and faeces at 168 hours. Started Nov 2021; status: completed.
02
Drugs
mefluleucine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05152680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05152680.